Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regenxbio (RGNX) Other Non-Current Assets (2016 - 2025)

Regenxbio has reported Other Non-Current Assets over the past 12 years, most recently at $4.6 million for Q4 2025.

  • Quarterly results put Other Non-Current Assets at $4.6 million for Q4 2025, up 15.33% from a year ago — trailing twelve months through Dec 2025 was $4.6 million (up 15.33% YoY), and the annual figure for FY2025 was $4.6 million, up 15.33%.
  • Other Non-Current Assets for Q4 2025 was $4.6 million at Regenxbio, up from $4.3 million in the prior quarter.
  • Over the last five years, Other Non-Current Assets for RGNX hit a ceiling of $4.8 million in Q4 2023 and a floor of $1.3 million in Q1 2021.
  • Median Other Non-Current Assets over the past 5 years was $2.0 million (2021), compared with a mean of $2.5 million.
  • Biggest five-year swings in Other Non-Current Assets: skyrocketed 136.8% in 2023 and later decreased 16.79% in 2024.
  • Regenxbio's Other Non-Current Assets stood at $2.0 million in 2021, then changed by 0.0% to $2.0 million in 2022, then skyrocketed by 136.8% to $4.8 million in 2023, then dropped by 16.79% to $4.0 million in 2024, then grew by 15.32% to $4.6 million in 2025.
  • The last three reported values for Other Non-Current Assets were $4.6 million (Q4 2025), $4.3 million (Q3 2025), and $1.9 million (Q2 2025) per Business Quant data.